M S Beyazal1, T Erdoğan2, G Devrimsel3, A K Türkyılmaz3, M C Cüre4, M Beyazal5, I Sahin2. 1. Department of Physical Medicine and Rehabilitation, School of Medicine, Recep Tayyip Erdoğan University, 53100, Rize, Turkey. drmunser@yahoo.com. 2. Department of Cardiology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey. 3. Department of Physical Medicine and Rehabilitation, School of Medicine, Recep Tayyip Erdoğan University, 53100, Rize, Turkey. 4. Department of Biochemistry, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey. 5. Department of Radiology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey.
Abstract
OBJECTIVE: Osteoprotegerin (OPG) is considered an important biomarker in cardiovascular (CV) disease. CV disease is the most common cause of mortality in patients with rheumatoid arthritis (RA), a consequence of accelerated atherosclerosis. The present study aimed to evaluate the relationship of serum OPG levels to arterial stiffness, carotid intima-media thickness (CIMT), and clinical and laboratory indices in RA patients. PATIENTS AND METHODS: Included in the study were 68 RA patients with no history or signs of CV disease and 48 healthy subjects Disease activity was assessed by the 28-joint disease activity score (DAS28) in RA patients. Serum OPG level was measured using enzyme-linked immunosorbent assay (ELISA). Carotid femoral pulse wave velocity (PWV) was measured as an index of arterial stiffness and CIMT was evaluated by carotid ultrasonography. RESULTS: The mean serum OPG level was significantly higher in RA patients than controls (p < 0.001). Mean PWV and CIMT were also significantly increased in RA patients compared to controls (both p < 0.001). In RA patients, serum OPG level was significantly correlated with PWV and CIMT, as well as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody; but not with DAS28, high-sensitivity C-reactive protein (hsCRP), or erythrocyte sedimentation rate. CONCLUSION: Serum OPG levels were increased and correlated with CIMT and PWV in RA patients. In addition to PWV and CIMT, OPG may be a useful biomarker for CV risk management in RA patients.
OBJECTIVE:Osteoprotegerin (OPG) is considered an important biomarker in cardiovascular (CV) disease. CV disease is the most common cause of mortality in patients with rheumatoid arthritis (RA), a consequence of accelerated atherosclerosis. The present study aimed to evaluate the relationship of serum OPG levels to arterial stiffness, carotid intima-media thickness (CIMT), and clinical and laboratory indices in RApatients. PATIENTS AND METHODS: Included in the study were 68 RApatients with no history or signs of CV disease and 48 healthy subjects Disease activity was assessed by the 28-joint disease activity score (DAS28) in RApatients. Serum OPG level was measured using enzyme-linked immunosorbent assay (ELISA). Carotid femoral pulse wave velocity (PWV) was measured as an index of arterial stiffness and CIMT was evaluated by carotid ultrasonography. RESULTS: The mean serum OPG level was significantly higher in RApatients than controls (p < 0.001). Mean PWV and CIMT were also significantly increased in RApatients compared to controls (both p < 0.001). In RApatients, serum OPG level was significantly correlated with PWV and CIMT, as well as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody; but not with DAS28, high-sensitivity C-reactive protein (hsCRP), or erythrocyte sedimentation rate. CONCLUSION: Serum OPG levels were increased and correlated with CIMT and PWV in RApatients. In addition to PWV and CIMT, OPG may be a useful biomarker for CV risk management in RApatients.
Authors: M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed Journal: Ann Rheum Dis Date: 2009-09-22 Impact factor: 19.103
Authors: Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala Journal: J Rheumatol Date: 2006-09-01 Impact factor: 4.666
Authors: Yu Asanuma; Cecilia P Chung; Annette Oeser; Joseph F Solus; Ingrid Avalos; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Tuulikki Sokka; Theodore Pincus; C Michael Stein Journal: Atherosclerosis Date: 2007-06-14 Impact factor: 5.162
Authors: Inmaculada Del Rincón; Ken Williams; Michael P Stern; Gregory L Freeman; Daniel H O'Leary; Agustín Escalante Journal: Arthritis Rheum Date: 2003-07